Zacks Investment Research upgraded shares of Kraton (NYSE:KRA) from a hold rating to a buy rating in a research report report published on Wednesday morning, Zacks.com reports.
Zacks Investment Research currently has $34.00 target price on the specialty chemicals company’s stock.
According to Zacks, “Kraton Corp is a producer of styrenic block copolymers, specialty polymers and performance products derived from pine wood pulping co-products.
The Polymer segment offers performance products, including styrene-butadiene-styrene for paving and roofing application; styrene-isoprene-styrene for personal care application; ethylene-vinyl acetate, polyolefins, and metallocene polyolefins for adhesives application; and specialty polymers, such as hydrogenated styrenic block copolymers, as well as isoprene rubber and isoprene rubber latex for use in medical and personal care products, adhesives, tackifiers, paints, and coatings.
Get a free copy of the Zacks research report on Kraton (KRA) For more information about research offerings from Zacks Investment Research, visit Zacks.com Receive News & Ratings for Kraton Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kraton and related companies with MarketBeat.com's FREE daily email newsletter.
Cidara Therapeutics (CDTX ) announces new data from the Phase 2 STRIVE trial of rezafungin, once-weekly echinocandin for treatment and prevention of fungal infections, and CD377 preclinical data for influenza protection.
New analyses from the completed mid-stage study support the efficacy and pharmacokinetics of rezafungin across a wide array of patient populations.
The trial demonstrated efficacy across multiple Candida species, with similar or better outcomes observed with rezafungin compared to standard of care, caspofungin.
In preclinical studies, a single dose of CD377 was protective against seasonal and pandemic influenza subtypes, demonstrating its potent broad-spectrum activity.
Cidara is currently conducting two Phase 3 trial with rezafungin - one for the treatment of candidemia and/or invasive candidiasis and another for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation.
Under the BARDA contract, TRI and its subcontractors Duke Clinical Research Institute (DCRI) and Syneos Health and Fisher Bioservices will provide full-service capabilities to support the implementation of the study.
The ACTIV public-private partnership selected three agents for the study from a pool of over 130 immune modulators initially reviewed based on several factors including their relevance to COVID-19, strong evidence for use against inflammatory reaction and cytokine storm and availability for large-scale clinical studies.
Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) is a public-private partnership led by the NIH and coordinated by the Foundation for the National Institutes of Health (FNIH) to develop a research strategy for prioritizing and speeding development of the most promising COVID-19 vaccines and treatments.
BETHESDA, Md., Oct. 20, 2020 /PRNewswire/ -- Technical Resources International, Inc. (TRI) has been awarded a contract to conduct the Randomized Master Protocol for Immune Modulators for Treating COVID-19 (ACTIV-1 IM) study under the Biomedical Advanced Research and Development Authority's (BARDA) Medical Countermeasures Clinical Studies Network, in collaboration with the National Institutes of Health (NIH).
About TRI Technical Resources International, Inc. (TRI) is a full-service contract research organization (CRO).
Fagron Sterile Services US (FSS), a top-tier DEA and FDA-registered 503B Outsourcing Provider, produces reliable supply of high-quality sterile medications with cGMP compliant operations for patient-focused healthcare facilities across North America.
At this time, LET Gel from Fagron Sterile Services US, is the only Sterile Topical LET Gel on the market from a 503B Outsourcing Facility or compounding pharmacy.
FSS leveraged pharmaceutical expertise spanning three decades to quickly develop the first Sterile Topical LET Gel in the industry - listening to both customer needs and the FDA.
503B Outsourcing Facility innovates topical LET anesthetic gel to produce the first widely available sterile option.
Company supports patient safety; innovating topical anesthetic gel to produce the first widely available sterile option from a 503B Outsourcing Facility - hospital emergency rooms, urgent care centers, pediatric offices and healthcare providers will benefit - WICHITA, Kan., Oct. 20, 2020 /PRNewswire/ -- Fagron Sterile Services US (FSS), a leading 503B pharmaceutical outsourcing provider, today announced a new product innovation - the launch of the first sterile topical anesthetic LET Gel produced at scale through cGMP compliant operations.
(NASDAQ: CBLI) shares shot up 140% to $5.22 after the company announced a definitive merger agreement to combine its business with Cytocom in an all-stock transaction.
Shares of Aptinyx Inc. (NASDAQ: APTX) got a boost, shooting 56% to $5.72 after the company announced positive results from the first Phase 2 study of its novel NMDA receptor modulator, NYX-783, in 153 patients with post-traumatic stress disorder.
Aurora Mobile Limited (NASDAQ: JG) shares were also up, gaining 32% to $2.88.
Equities Trading DOWN Baudax Bio, Inc. (NASDAQ: BXRX) shares tumbled 34% to $1.74 after the company issued commercial and corporate update.
Shares of Code Chain New Continent Limited (NASDAQ: CCNC) were down 29% to $1.62 after surging over 108% on Monday.
Statements by Crown and AUSTRAC on Monday revealed the federal agency was investigating whether Chinese VIP junket operators with links to organised crime used Crown's casino in Melbourne for illegal activities.
AUSTRAC officials came under fire from Labor Senator Louise Pratt and independent Senator Rex Patrick for failing to earlier pick up problems at Crown, after a 2017 AUSTRAC report concluded local casinos were "broadly" aware and compliant with their responsibilities in relation to high-risk junket operators.
The AUSTRAC probe follows revelations by Nine's 60 Minutes and The Age and The Sydney Morning Herald in July 2019 about Crown Melbourne's use of Chinese VIP junket operators with links to organised crime such as money laundering and other criminal activities.
The initial examination and the NSW casino inquiry warranted the case this month being elevated to an AUSTRAC enforcement investigation into Crown Melbourne that was publicly disclosed on Monday.
The AUSTRAC move means Crown is facing three separate investigations into relationships with VIP junket operators, including the NSW gaming inquiry and a probe by the Victorian Commission for Gambling and Liquor Regulation.
U.K. regulators have signed off on a Phase 1 clinical trial evaluating Intellia Therapeutics' (NTLA ) gene therapy NTLA-2001 in patients with transthyretin amyloidosis with polyneuropathy (hATTR-PN), a rare inherited disorder characterized by the buildup of amyloid protein in tissues and organs.
The primary objectives are safety, pharmacokinetics and pharmacodynamics, including the measurement of serum transthyretin levels following a single intravenous infusion.
Zacks Investment Research lowered shares of Quaker Chemical (NYSE:KWR) from a buy rating to a hold rating in a research report sent to investors on Saturday morning, Zacks.com reports.
According to Zacks, “Quaker Chemical Corporation develops, produces and markets a range of formulated chemical specialty products for various heavy industrial and manufacturing applications and, in addition, offers and markets chemical management services (CMS).
The specialty chemicals company reported $0.21 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.12 by $0.09.
Quaker Chemical Corporation develops, produces, and markets various formulated chemical specialty products for a range of heavy industrial and manufacturing applications.
Get a free copy of the Zacks research report on Quaker Chemical (KWR) For more information about research offerings from Zacks Investment Research, visit Zacks.com Receive News & Ratings for Quaker Chemical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quaker Chemical and related companies with MarketBeat.com's FREE daily email newsletter.
The Company has also granted the underwriters a 30-day option to purchase up to an additional 1,425,000 ADSs at the initial public offering price per ADS less underwriting discounts and commissions.
Forward-looking Statements Certain statements in this announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, regarding the Company's business as well as the proposed Offering.
Any statement describing Company goals, expectations, intentions or beliefs, including as they relate to the proposed Offering and its expected closing, is a forward-looking statement and should be considered an at-risk statement.
Such statements are subject to certain risks and uncertainties, including market conditions, the satisfaction of customary closing conditions relating to the Offering and the impact of general economic, industry or political conditions in Australia, the United States or internationally.
ASLAN Pharmaceuticals (NASDAQ:ASLN) plans to develop ASLAN003, its next-generation inhibitor of dihydroorotate dehydrogenase (DHODH), in autoimmune conditions such as multiple sclerosis (MS).
Based on the specificity, potency and favourable safety profile identified in earlier clinical studies, the company believes ASLAN003 is a promising candidate for development in MS and other autoimmune diseases.
The company expects to share further details in early 2021.
ASLAN003 has been shown to be more than 30 times more potent at inhibiting the DHODH enzyme than teriflunomide.
The records, combined with records in Italy, Portugal and Germany (and another 6k+ daily read in Spain) mean Europe is set to surpass the US in terms of total new cases yet again on Thursday.
Update (1330ET): Local leaders in Greater Manchester, the biggest British city facing BoJo's new "Tier 3" restrictions, set to begin over the weekend, are pushing back, claiming they won't allow their people to be "canaries in the coal mine" for an experimental new 'localized lockdown' strategy.
As EU members from Germany to Italy to the Czech Republic see COVID-19 cases surge, the global daily tally notched a new record on Wednesday, according to Johns Hopkins, which counted 380,426 new cases reported in the 24 hours to Wednesday.
The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
But when it comes to the states, the playbook mostly sets out that the federal government is responsible for staying in touch with states, tribes and territories, and those smaller jurisdictions are responsible for coming up with their own plans for rolling out vaccines.
Both Trump and the Centers for Disease Control and Prevention (CDC) told states to prepare for vaccines to arrive by the end of October.
'However, additional guidance and clarification is needed on the roles and expectations of states in a successful COVID-19 vaccine distribution and implementation plan.'
States are due to submit their plans for distributing coronavirus vaccines tomorrow, Friday October 16, according to the deadline set out by the Centers for Disease Control and Prevention's (CDC) vaccine 'playbook.'
New York Governor Andrew Cuomo is asking President Trump to meet with US governors and provide guidance on how coronavirus vaccines should be distributed once they are approved.
OAKLAND, Calif.: Facebook says it will ban ads on its platform that discourage vaccinations with an exception carved out for ads about government vaccine policies.
But Facebook also said Tuesday that ads that advocate for or against legislation or government policies around vaccines including a COVID-19 vaccine will still be allowed.
And unpaid posts by people or groups that discourage vaccinations will also still be allowed the new policy only includes paid advertisements.
Facebook is addressing the anti-vaxxers of 2014 and 2015 and not the anti-vaxxers of 2020, said David A. Broniatowski, an associate professor at George Washington Universitys school of engineering and applied science who has published several studies on vaccine misinformation.
Broniatowski published a study in 2019 that found that the majority of anti-vaccine misinformation being pushed in advertisements on Facebook were coming from two groups, including one led by Robert F. Kennedy Jr. and a California-based organization called Stop Mandatory Vaccination.
Russia's Gamaleya Research Institute of Epidemiology and Microbiology, which developed the vaccine, has still not shared additional research and data from early clinical trials testing the vaccine, the Moscow Times reported last week.
The UAE is the second foreign country to trial Russia's "Sputnik V" vaccine — named with a nod to the Cold War space race — following tests in Belarus, Reuters reported Monday.
During the call, the "importance of joint efforts to combat the spread of coronavirus was noted, including interaction on the Russian Sputnik V vaccine, which is currently being clinically tested in the UAE," the Kremlin said in a statement.
Russia has announced that human trials of its controversial coronavirus vaccine have begun in the United Arab Emirates (UAE).
Russia had already announced on its website dedicated to the vaccine that several countries, including the UAE as well as the Philippines, Saudi Arabia and "possibly India and Brazil," would partake in "post-registration clinical trials" of the vaccine.
BOSTON, Oct. 12, 2020 /PRNewswire/ -- The International Consortium for Health Outcomes Measurement (ICHOM) announced the release of their COVID-19 Standard Set (C19-SS) today.
To help institutions provide the best care for patients with COVID-19, health professionals and patient advisors from across the world have joined forces to establish and launch a global set of outcomes and measurement recommendations that reflect what matters most to patients with COVID-19.
The C19-SS is a core set of standards that tracks a patient's recovery through the measurement of 13 outcomes, which cover their social and mental functioning, quality of life, symptoms and relevant clinical outcomes.
The standard set was developed coupling the latest scientific knowledge from healthcare professionals and personal input from patients, ensuring the outcomes that matter most to them were placed as the central focus.
ICHOM's mission is to unlock the potential of value-based health care by defining global standard sets of outcome measures that matter most to patients and driving adoption and reporting of these measures worldwide to create better value for all stakeholders.
Any statement describing Company goals, expectations, intentions or beliefs, including as they relate to the proposed Offering, is a forward-looking statement and should be considered an at-risk statement.
Forward-looking Statements Certain statements in this ASX announcement may contain forward-looking statements regarding the Company's business as well as the proposed Offering.
About Opthea Opthea (ASX:OPT) is a biopharmaceutical company developing a novel therapy to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Such statements are subject to certain risks and uncertainties, including market conditions and the trading price of the Company's ordinary shares on the ASX.
Zacks Investment Research downgraded shares of Agenus (NASDAQ:AGEN) from a hold rating to a sell rating in a report released on Wednesday morning, Zacks.com reports.
Jefferies Financial Group boosted their price target on shares of Agenus from $5.00 to $8.00 and gave the company a buy rating in a research note on Friday, September 18th.
New York State Common Retirement Fund now owns 126,800 shares of the biotechnology company’s stock worth $498,000 after purchasing an additional 35,700 shares during the last quarter.
State Board of Administration of Florida Retirement System now owns 50,378 shares of the biotechnology company’s stock valued at $198,000 after purchasing an additional 29,154 shares in the last quarter.